Recent 8-K filings for INBP

• May 8, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Integrated BioPharma reports Q3 net loss of $0.8M, revenue falls 27.3% to $10.1M

  Net loss $0.8M ($0.03 loss per share) vs net income $0.6M ($0.02 EPS) in Q3 2025.

• April 15, 2026, 7:59 PM ET debt materiality 0.40 neutral item 9.01item 8.01

  Integrated BioPharma receives 3-month extension of PNC line of credit to July 14, 2026

  PNC Bank notified Integrated BioPharma and subsidiary Manhattan Drug on April 14, 2026.

• February 18, 2026, 6:59 PM ET other material materiality 0.45 neutral item 9.01

  Integrated Biopharma subsidiary amends lease with related party; rent increases to $1.1M/yr through 2029

  Manhattan Drug subsidiary reduced leased space from 116,175 to 110,095 sq ft at Hillside, NJ facility.

• February 11, 2026, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Integrated BioPharma Q2 revenue down 10.3%, swings to net loss of $0.8M

  Revenue $11.3M vs $12.6M Q2 prior year; operating loss $0.9M vs income $0.2M.

• December 1, 2025, 6:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01

  Shareholders re-elect director, approve 3-year say-on-pay frequency, ratify auditor

  Eric Friedman re-elected as Class III director with 20.66M votes for, 183k withheld, and 1.81M broker non-votes.

• November 10, 2025, 6:59 PM ET earnings materiality 0.50 negative item 2.02item 9.01

  Integrated BioPharma Q1 revenue down 6.6% to $12.7M; net income $0.1M, EPS $0.00

  Revenue $12.7M, down 6.6% from $13.6M YoY; gross profit $1.0M vs $1.4M.

• September 23, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Integrated BioPharma Q4 rev $14.2M (+11.8%); net loss $0.2M on tax; FY net income $808k

  Q4 revenue $14.2M vs $12.7M (+11.8%); operating income $589k vs $402k.

• May 14, 2025, 7:59 PM ET earnings materiality 0.55 positive item 2.02item 9.01

  Integrated BioPharma Q2 fiscal 2025 revenue up 6.1% to $13.9M, net income $0.6M

  Revenue $13.9M vs $13.1M YoY; nine-month revenue $40.2M (+6.9%).

• April 24, 2025, 7:59 PM ET other materiality 0.20 neutral item 4.01item 9.01

  Integrated BioPharma replaces auditor Marcum with CBIZ CPAs after Marcum's attest business acquisition

  Marcum LLP resigned as auditor effective April 24, 2025; CBIZ CPAs P.C. engaged for fiscal year ending June 30, 2025.

• April 21, 2025, 7:59 PM ET debt materiality 0.60 neutral item 1.02item 1.01item 2.03item 9.01

  Integrated BioPharma enters $4.5M PNC credit facility; replaces prior debt

  New $4M revolving line of credit and $500K convertible equipment line from PNC Bank (SOFR+250bps).

• February 13, 2025, 6:59 PM ET earnings materiality 0.55 positive item 2.02item 9.01

  Integrated BioPharma Q2 rev $12.6M (+9.6% YoY); net income $0.1M vs loss

  Revenue $12.6M for Q2 ended Dec 31, 2024, up from $11.5M a year ago; six-month rev $26.2M (+7.4%).

• December 2, 2024, 6:59 PM ET other material materiality 0.15 neutral item 5.07item 9.01

  Integrated BioPharma elects two Class I directors, ratifies Marcum as auditor at 2024 annual meeting

  Elected Damon DeSantis as Class I director: 20,448,871 for, 142,036 withheld, 1,342,353 broker non-votes.

• November 14, 2024, 6:59 PM ET earnings materiality 0.55 positive item 2.02item 9.01

  Integrated BioPharma Q1 revenue $13.6M (+5.4% YoY); net income $0.3M vs loss

  Revenue $13.6M versus $12.9M YoY; operating income $0.5M versus operating loss of $54K.

• September 23, 2024, 7:59 PM ET earnings materiality 0.50 neutral item 2.02item 9.01

  Integrated BioPharma Q4 net income $0.3M ($0.01/share); FY net income $112K vs loss $34K

  Revenue Q4 $12.7M (-2.3% YoY); FY $50.3M (-0.7% YoY).

• May 10, 2024, 7:59 PM ET earnings materiality 0.50 neutral item 2.02item 9.01 ◈ Earnings Releases

  Integrated BioPharma Q3 net income $0.3M vs $16k YoY; revenue flat at $13.1M

  Quarterly revenue $13.1M (flat YoY); operating income $0.4M vs $44k prior year.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.75 · Median 0.50 · Most common event earnings

3 positive 3 negative 9 neutral

source · INBP on sec.gov